Drugs / Lanabecestat
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT03499041 | Jun → Dec 2018 | — | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT03506399 | Jun → Oct 2018 | — | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT03545087 | Jun 2018 → Jan 2019 | impaired renal function disease | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT03222427 | Jan → Feb 2018 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03019549 | Jan → May 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02663128 | Jan → Mar 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02568397 | Oct 2015 → Jan 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02540668 | Sep 2015 → Jan 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02406261 | Apr → Aug 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02126514 | May 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02039180 | Feb → Mar 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02040987 | Jan → May 2014 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02010970 | Dec 2013 → Feb 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02005211 | Dec 2013 → Jul 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01795339 | Mar 2013 → Mar 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01739647 | Dec 2012 → May 2013 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02245737 | Sep 2014 → Oct 2018 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02972658 | Mar 2017 → Oct 2018 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT02783573 | Jul 2016 → Sep 2018 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lanabecestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02972658 ↗ |
| Known as | AZD3293 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02039180 ↗ |
| Known as | LANABECESTAT (AZD3293) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989948 ↗ |
| Known as | LY3314814 | “AZD3293 (also known as LY3314814) is a novel, potent, non-selective BACE1/BACE2 inhibitor currently in Phase 3 clinical development for the treatment of Alzheimer's disease.” PMID 29199322 ↗ 2016 |
| Action | Inhibit | “non-selective BACE1/BACE2 inhibitor” PMID 29199322 ↗ 2016 |
| Modality | Small molecule | — CHEMBL3989948 ↗ |
| Route | Oral | “Oral solution” NCT01795339 ↗ |
| Target | BACE1 | “non-selective BACE1/BACE2 inhibitor” PMID 29199322 ↗ 2016 |
| Target | BACE2 | “non-selective BACE1/BACE2 inhibitor” PMID 29199322 ↗ 2016 |